Brain natriuretic peptide in the contemporary management of congestive heart failure

References

• Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J.22, 1527–1560 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart S, MacIntyre K, MacLeod MMC, Bailey AEM, Capewell S, McMurray JJV. Trends in hospitalization for heart failure in Scotland, 1990–1996. Eur. Heart J.22, 209–217 (2001).
   PubMed Web of Science ®Google Scholar
• Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J. Am. Geriat. Soc.45, 270–275 (1997).
   PubMed Web of Science ®Google Scholar
• McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the REsource utilization Among COngestive Heart failure (REACH) study. J. Am. Coll. Cardiol.39, 60–69 (2002).
   PubMed Web of Science ®Google Scholar
• Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. J. Am. Med. Assoc.292, 344–350 (2004).
   PubMed Web of Science ®Google Scholar
• Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem. Biophys. Res. Commun.159, 1427–1434 (1989).
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides18, 1475–1481 (1997).
   Google Scholar
• Hunt PJ, Yandle TG, Nicholls G, Richards AM, Espiner EA. The amino-terminal portion of probrain natriuretic peptide (proBNP) circulates in human plasma. Biochem. Biophys. Res. Commun.214, 1449–1455 (1995).
   Google Scholar
• Abramson BL, Ando S, Notarius CF, Rongen GA, Floras JS. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation99, 1810–1815 (1999).
   PubMed Web of Science ®Google Scholar
• Arjona A, Hsu C, Wrenn D, Hill N. Effects of natriuretic peptides on vascular smooth-muscle cells derived from vascular beds. Gen. Pharmacol.28, 387–392 (1997).
   PubMedGoogle Scholar
• Laragh J. Atrial natriuretic hormone, the renin–aldosterone axis, and blood pressure-electrolyte homeostasis. N. Engl. J. Med.313, 1330–1340 (1985).
   PubMed Web of Science ®Google Scholar
• Kohno M, Yasunari K, Yokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J. Clin. Invest.876, 1999–2004 (1991).
   Google Scholar
• de Zeeuw D, Janssen WMT, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int.41, 1115–1133 (1992).
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal probrain natriuretic peptide (NT-PRO-BNP): a new marker of cardiac impairment. Clin. Endocrinol.47, 287–296 (1997).
   PubMed Web of Science ®Google Scholar
• Murdoch DR, Byrne J, Morton JJ et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart786, 594–597 (1997).
   Google Scholar
• Seino Y, Ogawa A, Yamashita T et al. Application of NT-pro-BNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Fail.6, 295–300 (2004).
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left-ventricular function and prognosis after myocardial infarction. Circulation97, 1921–1929 (1998).
   PubMed Web of Science ®Google Scholar
• Gerber IL, Stewart RAH, French JK et al. Associations between plasma natriuretic peptide levels, symptoms, and left-ventricular function in patients with chronic aortic regurgitation. Am. J. Cardiol.92, 755–758 (2003).
   PubMed Web of Science ®Google Scholar
• Sutton TM, Stewart RAH, Gerber IL et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J. Am. Coll. Cardiol.41, 2280–2287 (2003).
   PubMed Web of Science ®Google Scholar
• Gerber IL, Stewart RAH, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation107, 1884–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Kruger S, Graf J, Merx M et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am. Heart J.147, 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess O. Low probrain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation107, 1576–1578 (2003).
   PubMed Web of Science ®Google Scholar
• Kucher N, Printzen G, Goldhaber S. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation107, 2545–2547 (2003).
   PubMed Web of Science ®Google Scholar
• Lee S-C, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association Class during the out-patient treatment of heart failure. J. Card. Fail.8, 149–154 (2002).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left-ventricular diastolic function and right ventricular systolic function. J. Am. Coll. Cardiol.43, 416–422 (2004).
   PubMed Web of Science ®Google Scholar
• Kazanegra R, Cheng V, Garcia A et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J. Card. Fail.7, 21–29 (2001).
   PubMed Web of Science ®Google Scholar
• Catuzzo B, Ciancamerla F, Bobbio M, Longo M, Trevi G. In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern. J. Card. Fail.9, 303–310 (2003).
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodenheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KB, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol.40, 976–982 (2002).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol.90, 254–258 (2002).
   PubMed Web of Science ®Google Scholar
• Wallen T, Landahl S, Hedner K, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart77, 264–267 (1997).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J.147, 1078–1084 (2004).
   PubMed Web of Science ®Google Scholar
• Mark DB, Felker GM. B-type natriuretic peptide – a biomarker for all seasons. N. Engl. J. Med.350, 718–720 (2004).
   PubMed Web of Science ®Google Scholar
• Cataliotti A, Malatino LS, Jougasaki M et al. Circulating natriuretic peptide concentrations in patients with end stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin. Proc.76(11), 1111–1119 (2001).
   PubMed Web of Science ®Google Scholar
• Mehra M, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic levels in heart failure. J. Am. Coll. Cardiol.43, 1590–1595 (2004).
   PubMed Web of Science ®Google Scholar
• Missouris CG, Grouzmann E, Buckley MG, Barron J, MacGregor GA, Singer DRJ. How does treatment influence endocrine mechanisms in acute heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin. Sci.94, 591–599 (1998).
   Web of Science ®Google Scholar
• Davis M, Espiner EA, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet343, 440–444 (1994).
   PubMed Web of Science ®Google Scholar
• Rosseau M, Gurne O, Duprez D et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J. Am. Coll. Cardiol.40, 1596–1601 (2003).
   Web of Science ®Google Scholar
• Mizuno Y, Yasue H, Oshima S. Effects of ACE inhibitors on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J. Card. Fail.3, 287–293 (1997).
   PubMedGoogle Scholar
• Thomas AT, Kelly RF, Thomas SJ, Albasha K, Parrillo JE, Calvin JE. History, physical exam, ECG and chest x-ray do not differentiate normal from decreased systolic function in patients with congestive heart failure. Circulation100, 383 (1999).
   Google Scholar
• Remes J, Miettinen H, Reuanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary healthcare. Eur. Heart J.12, 315–321 (1991).
   PubMed Web of Science ®Google Scholar
• Clarke K, Gray D, Hampton J. Evidence of inadequate investigation and treatment of patients with heart failure. Br. Heart J.71, 584–587 (1994).
   PubMedGoogle Scholar
• Khunti K. Systematic review of open access echocardiography for primary care. Eur. J. Heart Fail.6, 79–83 (2004).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet350, 1349–1353 (1997).
   PubMed Web of Science ®Google Scholar
• Wright SP, Doughty RN, Pearl A et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J. Am. Coll. Cardiol.42, 1793–1800 (2003).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med.347, 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Campbell E, Frampton C, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol.42, 728–735 (2003).
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E et al. N-terminal probrain natriuretic peptide (NT-pro-BNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnea and ventricular dysfunction. Eur. J. Heart Fail.6, 301–308 (2004).
   PubMed Web of Science ®Google Scholar
• Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am. J. Cardiol.93, 1130–1135 (2004).
   PubMed Web of Science ®Google Scholar
• Logeart D, Saudubray C, Beyne P et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J. Am. Coll. Cardiol.40, 1794–1800 (2002).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Hollander JE, Guss D et al. Primary results of the Rapid Emergency Department Heart failure Out-patient Trial (REDHOT). J. Am. Coll. Cardiol.44, 1328–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med.350, 647–654 (2004).
   PubMed Web of Science ®Google Scholar
• Doughty R, Yee T, Sharpe N, MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988–1991. NZ Med. J.108, 473–475 (1995).
   PubMed Web of Science ®Google Scholar
• Juenger J, Schellberg D, Kraemer S et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart87, 235–241 (2002).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med.350, 655–663 (2004).
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chian Y-T et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation107, 1278–1283 (2003).
   PubMed Web of Science ®Google Scholar
• Isnard R, Pousset F, Chafirovskaia O et al. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in out-patients with chronic heart failure. Am. Heart J.146, 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher C, Berry C, Blue L, Morton JJ, McMurray JJV. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with heart failure. Heart89, 897–881 (2003).
   PubMed Web of Science ®Google Scholar
• Gwechenberger M, Hulsmann M, Berger R et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J. Heart Lung Transplant.23, 839–844 (2004).
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand IS et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J.25, 292–299 (2004).
   PubMed Web of Science ®Google Scholar
• de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C. B-type natriuretic peptide and peak oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J. Am. Coll. Cardiol.43, 1584–1589 (2004).
   PubMed Web of Science ®Google Scholar
• Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J. Am. Coll. Cardiol.43, 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann. Emerg. Med.39, 131–138 (2002).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the International Society for Heart and Lung Transplantation. Endorsed by the Heart Failure Society of America. J. Am. Coll. Cardiol.38, 2101–2113 (2001).
   PubMed Web of Science ®Google Scholar
• Kinnunen P, Vuolteenaho O, Rushkaoho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology132, 1961–1970 (1993).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med.345, 1014–1021 (2001).
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation106, 2913–2918 (2002).
   PubMed Web of Science ®Google Scholar
• Jernberg T, Stridsberg M, Venge P, Lindhahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J. Am. Coll. Cardiol.40, 437–445 (2002).
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls G, Espiner EA et al. B-type natriuretic peptide and ejection fraction for prognosis after myocardial infarction. Circulation107, 2786–2792 (2003).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left-ventricular dysfunction. Australia–New Zealand Heart Failure Group. J. Am. Coll. Cardiol.37, 1781–1787 (2001).
   PubMed Web of Science ®Google Scholar
• Sadanandan S, Cannon CP, Chekuri K et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol.44, 564–568 (2004).
   PubMed Web of Science ®Google Scholar
• Mega JL, Morrow DA, de Lemos JA et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J. Am. Coll. Cardiol.44, 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Braunwald E, Moye L et al. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med.327, 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of ‘asymptomatic’ left-ventricular systolic dysfunction: implications for screening. Ann. Intern. Med.138, 907–916 (2003).
   Google Scholar
• Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left-ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. J. Am. Med. Assoc.288, 1252–1259 (2002).
   PubMed Web of Science ®Google Scholar
• Ng L, Loke I, Davies JE et al. Identification of previously undiagnosed left-ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur. J. Heart Fail.5, 775–782 (2003).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart87, 131–135 (2002).
   PubMed Web of Science ®Google Scholar
• McDonagh T, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet351, 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Groenning BA, Raymond I, Hildebrant P, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left-ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart90, 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Nielsen OW, McDonagh T, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left-ventricular systolic dysfunction in the general population. J. Am. Coll. Cardiol.40, 113–120 (2003).
   Google Scholar
• Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left-ventricular ejection fraction. J. Am. Coll. Cardiol.43, 1019–1026 (2004).
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Ansari M, Schiller NB, Massie BM, Whooley MA. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am. J. Med.116, 509–516 (2004).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left-ventricular dysfunction. Am. Heart J.141, 367–374 (2001).
   PubMed Web of Science ®Google Scholar
• Androne AS, Hryniewicz K, Hudaihed A, Mancini D, LaManca J, Katz SZ. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am. J. Cardiol.93, 1254–1259 (2004).
   PubMed Web of Science ®Google Scholar
• Warner Stevenson L, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. J. Am. Med. Assoc.261, 884–888 (1989).
   Web of Science ®Google Scholar
• Warner Stevenson L, Dracup KA, Tillish JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am. J. Cardiol.63, 461–464 (1989).
   PubMed Web of Science ®Google Scholar
• Steimle AE, Warner Stevenson L, Chelimsky-Fallick C et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation96, 1165–1172 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng V, Kazanegra R, Garcia A et al. A rapid test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol.37, 386–391 (2001).
   PubMed Web of Science ®Google Scholar
• Murdoch DR, McDonagh T, Byrne J et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J.138, 1126–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet355, 1126–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Stanek B, Frey B, Hulsmann M et al. Prognostic evaluation of neurohormonal plasma levels before and during α-blocker therapy in advanced left-ventricular dysfunction. J. Am. Coll. Cardiol.38, 436–442 (2001).
   PubMed Web of Science ®Google Scholar
• Takeda Y, Fukutomi T, Suzuki S et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am. J. Cardiol.94, 448–453 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshizawa A, Yoshikawa T, Nakamura I et al. Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J. Card. Fail.10, 310–315 (2004).
   PubMed Web of Science ®Google Scholar
• Hobbs RE, Miller LF, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol.78, 896–901 (1996).
   PubMed Web of Science ®Google Scholar
• Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. J. Am. Coll. Cardiol.34, 155–162 (1999).
   PubMed Web of Science ®Google Scholar
• Marcus LS, Hart D, Packer M et al. Myocardial disease: hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation94, 3184–3189 (1996).
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med.343, 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol.39, 798–803 (2002).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Horton DP, LeJemtel TH et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with congestive heart failure: the PRECEDENT study. Am. J. Cardiol.144, 1102–1108 (2002).
   Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs. nitroglycerine for treatment of decompensated congestive heart failure: a randomized controlled trial. J. Am. Med. Assoc.287, 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Elkayam U, Akhter MW, Singh H, Kahn S, Usman A. Comparison of effects on left-ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am. J. Cardiol.93, 237–240 (2004).
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am. J. Cardiol.92, 631–633 (2003).
   PubMed Web of Science ®Google Scholar
• Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and noncardiac dyspnea. Eur. J. Heart Fail.6, 63–70 (2004).
   PubMed Web of Science ®Google Scholar
• MacDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-pro-BNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur. J. Heart Fail.6, 269–273 (2004).
   PubMed Web of Science ®Google Scholar